Zydus Lifesciences secures USFDA okay for Lenalidomide Capsules to treat cancer

The drugs will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad.

Published On 2023-03-09 09:45 GMT   |   Update On 2023-03-09 09:45 GMT

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Lenalidomide Capsules, 2.5 mg and 20 mg (USRLD: Revlimid Capsules).Lenalidomide Capsules are used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with...

Login or Register to read the full article

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Lenalidomide Capsules, 2.5 mg and 20 mg (USRLD: Revlimid Capsules).

Lenalidomide Capsules are used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions.

The products will be launched in the US market shortly.

The drugs will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad (India).

Lenalidomide Capsules had annual sales of USD 183 mn in the United States (IQVIA MAT Dec. 2022). The group now has 349 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Read also: USFDA approves Zydus Lifesciences Infantile spasm drug Vigabatrin

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.

Read also: Zydus Lifesciences cold sores cream Acyclovir bags USFDA okay

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News